Why India rejected a patent application for shorter drug-resistant TB treatment | Explained

The decision could open the door to greater generic competition, but its impact on treatment costs will depend on drug availability, pricing, and access to care
Read the full report on The Hindu
Story file
How this page works. The Headline Update lists this report from The Hindu with a short summary and a link to the original. The original reporting and photograph belong to the publisher. Spotted an error in our summary? Tell our corrections desk.





